Why Elfabrio—the PEGylated ERT—may be an option for your patients1,2:

Circulating enzymes between infusions increase over time

Elfabrio has an overall mean half-life of ~80 hours* (from 53 to 121 hours), with blood levels that increase with repeat administration1,2

* Elfabrio has an initial half-life of 78.9 ± 10.3 hours. Clinical studies have not established that pharmacological characteristics, including half-life, result in superior efficacy or safety based on clinically relevant endpoints. Infusions are every 2 weeks.1

Comparable efficacy to agalsidase beta observed

Annualized rate of change in estimated glomerular filtration rate (eGFR) mean slope was similar for both Elfabrio and agalsidase beta groups in a 2-year study1

Established tolerability

Safety profile was assessed through long-term clinical trials including a head-to-head trial with an agalsidase beta control group1,3,4

Low immune response

Patients who switched to Elfabrio from agalsidase beta experienced a low rate of new anti-drug antibodies (ADAs) (11.5%)1,5†

The effect of IgG ADAs on the effectiveness of Elfabrio has not been fully characterized. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
ERT, enzyme replacement therapy; IgG, immunoglobulin G; PEG, polyethylene glycol.

Elfabrio has been validated by a robust, broad-ranging clinical trial program in Fabry disease1,3-7

Broad patient population

Male and female adults, classic or nonclassic Fabry, varying organ function, varying treatment history

Multiple global clinical studies

Controlled pivotal trials and long-term, open-label follow-up across a variety of Fabry patients

See the whole picture and learn what Elfabrio may do for your patients.

Dosing and administration designed with patients in mind1

  • Initial infusions (first 4-6 doses) take as little as 3 hours for ERT-experienced patients based on patient weight and previous ERT experience. Initial infusions should be at least 4 hours for patients who have not been treated with an ERT in the past 6 months
  • If the patient is switching from a prior ERT with an infusion duration greater than 3 hours, start Elfabrio at the same infusion rate
  • Infusion duration may be decreased by 30 minutes after the initial infusions and at every third follow-up infusion to the minimum recommended duration of 1.5 hours
  • Consider whether tolerability has been established at each of these intervals and adjust the infusion rate at your discretion

Once tolerability has been established after the initial 4-6 infusions…

Maintenance infusions in as little as 90 minutes

following gradual decreases in infusion duration1

Infusions in the clinic or at home are available for eligible patients at your discretion1‡

Patients receiving treatment or residing in MA or RI are not eligible for home infusion services. To receive home infusion support, patients must be referred to home infusion by their prescribing physician. Please see the full Terms and Conditions for additional eligibility requirements.

Which potential patients may be right for Elfabrio?